Herantis Pharma granted almost €3 million government loan for Parkinson’s study

News

Author: Parkinson's Life editorsPublished: 15 August 2015

Parkinson's LifePrep: Parkinson's LifeCook: Parkinson's LifeServes:

News image

Tekes, the Finnish Funding Agency for Innovation, has granted a €2,903,000 loan to Herantis Pharma Plc to support its clinical study of CDNF for the treatment of Parkinson’s disease. The loan was granted conditionally, subject to obtaining regulatory approval for the clinical study.

Pekka Simula, CEO of Herantis Pharma, added: “We are very excited about our opportunity to translate the results of years of leading academic research to clinical stage, hopefully for the benefit of as many patients as possible.”

Herantis aims to start its clinical development programme with regulatory submissions in Finland and Sweden by the end of 2015. Patient treatments are expected to begin in the first half of 2016. The company expects to recruit 18 patients with Parkinson’s disease in this first-in-human study of CDNF.

Go Back

Share this story

Comments


Related articles


Head injury

Special reports

A single head injury could increase risk of Parkinson’s

A study has found a link between head injuries and Parkinson’s

READ MORE
Headshot of comedian and writer Paul Mayhew-Archer

Global update

What if Father Christmas had Parkinson’s disease?

Paul Mayhew-Archer pens a new festive poem

READ MORE
Harry Styles' mum wing walks for Parkinson's

Global update

Harry Styles’ mum Anne Twist wing walks for Parkinson’s

The campaign has raised over £10,000 for Parkinson’s disease so far

READ MORE